* APTYS PHARMACEUTICALS *
2002 - Centre
Clermont-Ferrand
www.aptys-pharmaceuticals.com Contract, Research
(also, Delivery, Drugs)
Key words: Formulation, Peptides, ADHAPT, Bi-Gel, Generic Plus, Insulin delivery
Mission: to develop formulation of new chemical entities and peptides/proteins, reformulation of registered molecules and novel drug delivery systems for third parties, to develop internal research programs for own technological portfolio, based on subcontractor cash flow
Clients: Pharmaceutical industry, Biotechs
contact@aptys-pharmaceuticals.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Spin-off |
Managing Dir.: Boutignon (François) [co-founder, born 1960, Ph.D. protein biochemistry, ex-Europeptides]
Sc.Dir.: Boutignon (François)
Fin.Dir.:
BusDev:
Financers: privately owned (capital 2007 = 0.10 M€) | Turnover (M€) : 0.44 (2007)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2007 .05 | Clinical trial (phase III) for a new formulation product based on the Bi-Gel technology in the USA (beginning) | CLIN | [5 years] |
| 2004 .02 | Launch of new trade mark as «The Formulation Company» | MKTG | [2 years] |
| 2002 .11 | Company founded by François Boutignon, Jean-Marc Aiache [Pharm.D., Ph.D., Professor Emeritus], and Michel G. Lepers [Professor of Technology transfer at University of Auvergne, founder-CEO Eurobiobiz], as a spin-off of the University of Auvergne | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
